Clinical trial
A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
NCT02302469 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
- Lead sponsor
- University Hospital, Lille
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 31, 2009
- Completion date
- April 30, 2017
- Enrollment
- 17 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.